## Clinical Context This patient has **Barrett's esophagus** (columnar metaplasia with goblet cells in the distal esophagus), a complication of chronic GERD. The absence of dysplasia is a critical finding that determines management strategy. ## Pathophysiology of Barrett's Esophagus **Key Point:** Barrett's esophagus is metaplasia—replacement of squamous epithelium with columnar mucosa—in response to chronic acid reflux. It is a premalignant condition but NOT dysplasia itself. **High-Yield:** The risk of progression to adenocarcinoma depends on the **grade of dysplasia**: - **Non-dysplastic Barrett's** → ~0.2–0.5% annual progression to cancer - **Low-grade dysplasia (LGD)** → ~2–5% annual progression - **High-grade dysplasia (HGD)** → ~5–10% annual progression (or already has occult cancer in 30–40%) ## Management by Dysplasia Grade | Dysplasia Grade | Management | |---|---| | **Non-dysplastic Barrett's** | PPI therapy + surveillance endoscopy every 2–3 years | | **Low-grade dysplasia** | Confirm with expert pathologist; surveillance every 6–12 months OR ablation if extensive | | **High-grade dysplasia** | Confirm with repeat biopsy; endoscopic therapy (EMR/ablation) or esophagectomy | ## Why This Answer Since there is **no dysplasia**, the patient has non-dysplastic Barrett's esophagus. Management focuses on: 1. **Acid suppression:** PPI therapy reduces reflux and may slow progression of metaplasia. 2. **Surveillance:** Endoscopy every 2–3 years detects dysplasia or cancer early. **Clinical Pearl:** The goal is not to reverse metaplasia (which is difficult) but to prevent progression to dysplasia and cancer through acid control and surveillance. ## Why NOT Endoscopic Mucosal Resection EMR is reserved for: - **High-grade dysplasia** (confirmed on repeat biopsy) - **Early invasive adenocarcinoma** (T1a) EMR for non-dysplastic Barrett's is not indicated and would cause unnecessary morbidity (stricture, perforation). ## Why NOT Immediate Esophagectomy Esophagectomy is a major surgery reserved for: - **HGD** (in selected patients with extensive disease) - **Invasive adenocarcinoma** with adequate performance status Non-dysplastic Barrett's does not warrant esophagectomy. The cancer risk is low (~0.2% per year), and surveillance is the standard approach. ## Why NOT Repeat Endoscopy in 1 Week Repeat endoscopy in 1 week is unnecessary. The diagnosis of Barrett's is confirmed by the biopsy. Surveillance should be scheduled at 2–3 years, not 1 week. Repeating in 1 week would waste resources and delay appropriate long-term surveillance planning.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.